Niels Espeland - Prenetics Global President - International Operations
| PRE Stock | USD 5.23 0.10 1.88% |
President
Mr. Niels Espeland is President International Operations of Precision Drilling Corporationrationration. From 2007 to 2011 Mr. Espeland was Group Vice President Drilling for Weatherford International and from 2001 to 2007 was Managing Director Middle East and Africa for KCA Deutag. since 2011.
| Tenure | 13 years |
| Address | Unit 701-706, Quarry Bay, Hong Kong |
| Phone | 852 2210 9588 |
| Web | https://www.prenetics.com |
Prenetics Global Management Efficiency
The company has Return on Asset of (0.106) % which means that on every $100 spent on assets, it lost $0.106. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2487) %, meaning that it generated no profit with money invested by stockholders. Prenetics Global's management efficiency ratios could be used to measure how well Prenetics Global manages its routine affairs as well as how well it operates its assets and liabilities. As of May 4, 2024, Return On Tangible Assets is expected to decline to -0.31. The current year's Return On Capital Employed is expected to grow to -0.23. At present, Prenetics Global's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 13.2 M, whereas Other Assets are forecasted to decline to about 6.7 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Laura Furmanski | Qiagen NV | N/A | |
| Dietrich Hauffe | Qiagen NV | N/A | |
| Manuel Mendez | Qiagen NV | 42 | |
| Mark Mozola | Neogen | 59 | |
| Jerome Hagedorn | Neogen | 51 | |
| Ulrich Schriek | Qiagen NV | N/A | |
| Shane Fitzwater | Neogen | 43 | |
| Joseph Corbett | Neogen | 48 | |
| Thomas Schweins | Qiagen NV | N/A | |
| MD DO | Aclaris Therapeutics | 54 | |
| Brad Crutchfield | Qiagen NV | 52 | |
| Kenneth Kodilla | Neogen | 59 | |
| Neal DO | Aclaris Therapeutics | 54 | |
| Toby Juvenal | Castle Biosciences | 63 | |
| Annette Koch | Qiagen NV | N/A | |
| Carl Raimond | Olink Holding AB | 53 | |
| Barthold Piening | Qiagen NV | 59 | |
| Helge Lubenow | Qiagen NV | N/A | |
| Benedikt Braunmuehl | Qiagen NV | N/A | |
| Luciano Bonanni | Fonar | 69 | |
| Stewart Bauck | Neogen | 59 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 |
Prenetics Global Leadership Team
Elected by the shareholders, the Prenetics Global's board of directors comprises two types of representatives: Prenetics Global inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prenetics. The board's role is to monitor Prenetics Global's management team and ensure that shareholders' interests are well served. Prenetics Global's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prenetics Global's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Darren Ruhr, Senior Vice President - Corporate Services | ||
| Catherine Hughes, Independent Director | ||
| Kevin Meyers, Independent Director | ||
| Yung DPHIL, Chief Officer | ||
| Samantha Kwok, People President | ||
| Judith Hanratty, Independent Director | ||
| William Donovan, Independent Director | ||
| Kevin Twomey, Independent Director | ||
| JeanPaul Montupet, Chairman of the Board | ||
| Hoi Lo, Chief Officer | ||
| Walt Ling, Chief Genomics | ||
| Douglas Evasiuk, Senior Vice President - Sales and Marketing, North America | ||
| Gene Stahl, President - Drilling Operations | ||
| Veronica Foley, Vice President - Legal, Corporate Secretary | ||
| Senthil MD, Chief Officer | ||
| Emmanuel Clarke, CEO of Partnerre Global | ||
| Niels Espeland, President - International Operations | ||
| Laurie Desmet, Chief Operations Officer and Executive VP | ||
| Kevin Neveu, President CEO, Non-Independent Director | ||
| Avrom Lasarow, Chief EMEA | ||
| Debra Perry, Director | ||
| Charles Goldie, CEO - PartnerRe Global | ||
| William Babcock, CFO and Executive VP | ||
| Stephen Letwin, Independent Director | ||
| Chi Tzang, Chief CoFounder | ||
| Egbert Willam, Independent Director | ||
| ShihChang MD, Chief Board | ||
| Robin Sidders, Investor Relations Director | ||
| Yvonne Wong, Chief Officer | ||
| Remy Sautter, Independent Director | ||
| Marvin Pestcoe, Interim CEO of Life & Health | ||
| Sheng Yeung, Chairperson CoFounder | ||
| Jan Holsboer, Independent Director | ||
| Darcy Falardeau, Vice President - Precision Well Servicing | ||
| Steven Krablin, Independent Director | ||
| Robert Phillips, Independent Chairman of the Board | ||
| Roberto Mendoza, Independent Director | ||
| Allen Hagerman, Independent Director | ||
| Greg Seow, Director | ||
| Theodore Walker, CEO of Partnerre North America | ||
| Carey Ford, Senior Vice President - Operations Finance and interim CFO | ||
| Brian Gibson, Independent Director | ||
| David Zwiener, Interim CEO, Interim President, Director and Member of Risk and Fin. Committee | ||
| Joel Neoh, Chief CircleDNA |
Prenetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prenetics Global a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (2.88) % | ||||
| Operating Margin | (2.11) % | ||||
| Current Valuation | (8.02 M) | ||||
| Shares Outstanding | 10.62 M | ||||
| Shares Owned By Insiders | 21.17 % | ||||
| Shares Owned By Institutions | 14.24 % | ||||
| Number Of Shares Shorted | 31.84 K | ||||
| Price To Earning | 144.87 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prenetics Global using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prenetics Global. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Prenetics Stock refer to our How to Trade Prenetics Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Prenetics Stock analysis
When running Prenetics Global's price analysis, check to measure Prenetics Global's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prenetics Global is operating at the current time. Most of Prenetics Global's value examination focuses on studying past and present price action to predict the probability of Prenetics Global's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prenetics Global's price. Additionally, you may evaluate how the addition of Prenetics Global to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Prenetics Global's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prenetics Global. If investors know Prenetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prenetics Global listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.83) | Revenue Per Share 1.933 | Quarterly Revenue Growth (0.90) | Return On Assets (0.11) | Return On Equity (0.25) |
The market value of Prenetics Global is measured differently than its book value, which is the value of Prenetics that is recorded on the company's balance sheet. Investors also form their own opinion of Prenetics Global's value that differs from its market value or its book value, called intrinsic value, which is Prenetics Global's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prenetics Global's market value can be influenced by many factors that don't directly affect Prenetics Global's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prenetics Global's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prenetics Global is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prenetics Global's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.